Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
AssigneeMerck Sharp & Dohme Corp.
InventorsEmma Joanne Carlson, Nadia Melanie Rupniak
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
Claims13
A method for the treatment of depression or anxiety, which method comprises the oral administration to a patient in need of such treatment or prevention of an amount of a NK-1 receptor antagonist and an amount of an antidepressant or anti-anxiety agent selected from:
- buspirone, citalopram, femoxetine, fluvoxamine, norfluoxetine, paroxetine, sertraline, venlafaxine, and pharmaceutically acceptable salts thereof;
- such that together they give effective relief, wherein said NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
A method for the treatment of depression and/or anxiety, which method comprises oral administration to a patient in need of such treatment or prevention an amount of a NK-1 receptor antagonist and an amount of sertraline, or a pharmaceutically acceptable salt thereof, such that together they give effective relief, wherein the NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
A method for the treatment of depression and/or anxiety, which method comprises oral administration to a patient in need of such treatment or prevention an amount of a NK-1 receptor antagonist and an amount of paroxetine, or a pharmaceutically acceptable salt thereof, such that together they give effective relief, wherein the NK-1 receptor antagonist is CNS-penetrant as determined by its ability to inhibit NK-1 receptor agonist-induced foot-tapping in the gerbil, and is effective in the attenuation of separation-induced vocalisations by guinea-pig pups.
Dependencies are inferred from the claim text.